Skip to main content
RESMED INC logo

RESMED INC — Investor Relations & Filings

Ticker · RMD LEI · 254900O2VD7IQ5OGI615 ASX Manufacturing
Open in API
Filings indexed 1,641 across all filing types
Latest filing 2022-10-05 Proxy Solicitation & In…
Country AU Australia
Listing ASX RMD

About RESMED INC

https://www.resmed.com

ResMed Inc. is a global leader in the development, manufacturing, and distribution of medical devices and cloud-based software solutions for the management of sleep-disordered breathing, chronic obstructive pulmonary disease, and other respiratory conditions. The company’s primary product portfolio includes continuous positive airway pressure (CPAP) devices, bilevel machines, and a variety of masks and accessories designed to improve patient adherence and comfort. ResMed distinguishes itself through its focus on digital health, offering integrated software platforms that enable remote patient monitoring and data-driven clinical insights for healthcare providers. Additionally, the company provides software-as-a-service (SaaS) solutions to support out-of-hospital care settings, including home health, hospice, and skilled nursing facilities, aiming to improve patient outcomes and reduce overall healthcare costs.

Recent filings

Filing Released Lang Actions
Notice of Annual General Meeting/Proxy Form 95 pages 6.5MB
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, which is used to solicit shareholder votes for an upcoming annual meeting. It includes detailed information about the meeting date, voting instructions, proposals to be voted on (such as election of directors, ratification of auditors, and executive compensation approval), biographies of directors and executive officers, corporate governance details, and compensation discussion and analysis. The presence of voting instructions, meeting notice, and detailed proxy materials indicates this is a Proxy Solicitation & Information Statement. It is not an Annual Report, Earnings Release, or other financial report, but rather a document designed to inform shareholders and solicit their votes for the annual meeting.
2022-10-05 English
Notice of Annual General Meeting Additional Materials 3 pages 234.0KB
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, specifically for the 2022 Annual Meeting of ResMed Inc. It includes details about voting items such as election of directors, ratification of auditors, and advisory approval of executive compensation. The document is clearly a proxy solicitation material intended to inform shareholders and solicit their votes for the annual meeting. It is not the actual annual report, earnings release, or any other financial report. The document length is 4265 characters, which is relatively short and consistent with proxy statements. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI).
2022-10-05 English
Statement of CDIs on issue - RMD 4 pages 23.0KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Statement of CDIs on Issue' and details the number and class of CHESS Depositary Interests (CDIs) and other securities on issue for ResMed Inc. It includes monthly figures for September 2022, net differences in securities, and reasons for changes such as transfers and new shares issued under employee plans. There is no financial performance data, earnings information, or management discussion. The document is a regulatory announcement about the securities issued and changes in share capital representation, specifically focusing on CDIs and related securities. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes.
2022-10-05 English
Statement of CDIs on issue - RMD 4 pages 22.9KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Statement of CDIs on Issue' and details the number and class of CHESS Depositary Interests (CDIs) and other securities on issue for ResMed Inc. It includes monthly figures for August 2022, net differences in securities issued, and reasons for changes such as transfers and new shares issued under employee plans. There is no financial performance data, earnings information, or management discussion. The document is a regulatory announcement about the company's securities issued and changes in share capital representation, specifically related to CDIs and stock options. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes. The document length is 3081 characters, which is consistent with a detailed announcement rather than a full report. Therefore, the appropriate classification is SHA with high confidence.
2022-09-06 English
Update - Dividend/Distribution - RMD 4 pages 26.5KB
Notice of Dividend Amount Classification · 100% confidence The document is titled 'Notification of dividend / distribution' and contains detailed information about dividend payment dates, amounts, currency, withholding tax rates, record dates, and exchange rates. It specifically updates a previous announcement regarding the foreign exchange rate for an upcoming dividend. The content focuses on dividend details and payment logistics rather than financial results or management commentary. The document length is 6151 characters, which is sufficient to contain substantive dividend information rather than just a brief announcement. Therefore, this document fits the category of a Notice of Dividend Amount (DIV).
2022-08-18 English
ResMed Form 10-k Annual Report 102 pages 655.9KB
Annual Report Classification · 100% confidence The document is titled 'FORM 10-K' and is described as an 'ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934' for the fiscal year ended June 30, 2022. It includes detailed sections typical of a 10-K filing such as Business, Risk Factors, Legal Proceedings, Management's Discussion and Analysis, Financial Statements, and Executive Compensation. The length of the document is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of detailed financial and operational information confirms it is the official annual report covering company activity and full financial performance. FY 2022
2022-08-14 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.